Captura Biopharma, an operator of a biotechnology company, agreed to go public via a SPAC merger with OceanTech Acquisitions I in a $224m. “We believe that our solution could revolutionize the treatment for heavy metal poisoning and catastrophic emergency internal transuranic radiation contamination by offering a unique, easy to administer oral therapy for heavy metal poisoning. This therapy is designed to be highly scalable and to reduce logistical and medical complexity compared to the currently available emergency countermeasures. As we continue our journey, we believe the merger with OceanTech will provide us with greater opportunity to take advantage of improved access to capital markets and to finance our growth," Michael Geranen, Captura Biopharma CEO and Founder.